Bcl2-negative MCF7 cells overexpress p53: implications for the cell cycle and sensitivity to cytotoxic drugs

被引:14
作者
Poliseno, L
Mariani, L
Collecchi, P
Piras, A
Zaccaro, L
Rainaldi, G
机构
[1] CNR, Ist Fisiol Clin, Lab Terapia Gen & Mol, Area Ric, I-56124 Pisa, Italy
[2] Univ Pisa, Dipartimento Oncol Mol, Pisa, Italy
[3] Univ Pisa, Ctr Retrovirus, Pisa, Italy
关键词
Bcl2; p53; cell cycle; drug sensitivity; apoptosis;
D O I
10.1007/s00280-002-0467-x
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: Bcl2 is a mitochondrial protein endowed with cytostatic and antiapoptotic activities. In this work we studied the effects of the lack of Bcl2 in MCF7 cells. Methods: The breast cancer cell line MCF7 (Bcl2-positive) and its derivative MCF7/5013 (Bc12-negative) were compared in terms of the level of p53 expression, doubling time and distribution of cells among the cycle phases. Sensitivities to the proapoptotic drugs cisplatinum and staurosporine were measured using a clonogenic assay and the contribution of apoptosis to cytotoxicity was determined with a mitochondrial membrane potential-sensitive dye. Results: Relative to MCF7, MCF7/5013 cells overexpressed p53 and slowly proliferated with a significant accumulation at G(0)/G(1) and depletion in S phase. The cytotoxicity of the DNA-damaging agent cisplatinum was decreased, while that of the protein kinase inhibitor staurosporine was increased. The induced cytotoxicity was essentially due to apoptosis and necrosis, respectively. Conclusions: These results suggest that the lack of Bcl2 accompanied by p53 overexpression affects the distribution of cells among the cell cycle phases and modifies the sensitivity to cytotoxic drugs and the type of cell death.
引用
收藏
页码:127 / 130
页数:4
相关论文
共 27 条
[1]   Mechanisms of p53-mediated apoptosis [J].
Bates, S ;
Vousden, KH .
CELLULAR AND MOLECULAR LIFE SCIENCES, 1999, 55 (01) :28-37
[2]  
Blanc C, 2000, CANCER RES, V60, P4386
[3]  
Chiarugi V, 1996, TUMORI, V82, P205
[4]   CYTOTOXICITY OF THE ANTICANCER AGENTS CISPLATIN AND TAXOL DURING CELL-PROLIFERATION AND THE CELL-CYCLE [J].
DONALDSON, KL ;
GOOLSBY, GL ;
WAHL, AF .
INTERNATIONAL JOURNAL OF CANCER, 1994, 57 (06) :847-855
[5]  
FAN SJ, 1995, CANCER RES, V55, P1649
[6]   p53 and chemosensitivity [J].
Ferreira, CG ;
Tolis, C ;
Giaccone, G .
ANNALS OF ONCOLOGY, 1999, 10 (09) :1011-1021
[7]   Inhibition of p53 transcriptional activity by Bcl-2 requires its membrane-anchoring domain [J].
Froesch, BA ;
Aimé-Sempé, C ;
Leber, B ;
Andrews, D ;
Reed, JC .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (10) :6469-6475
[8]   Interaction with p53 enhances binding of cisplatin-modified DNA by high mobility group 1 protein [J].
Imamura, T ;
Izumi, H ;
Nagatani, G ;
Ise, T ;
Nomoto, M ;
Iwamoto, Y ;
Kohno, K .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (10) :7534-7540
[9]   Molecular mechanisms involved in cisplatin cytotoxicity [J].
Jordan, P ;
Carmo-Fonseca, M .
CELLULAR AND MOLECULAR LIFE SCIENCES, 2000, 57 (8-9) :1229-1235
[10]   Preclinical perspectives on platinum resistance [J].
Kelland, LR .
DRUGS, 2000, 59 (Suppl 4) :1-8